Violet Therapeutics raised $4.8 million in a seed extension financing as it advances its RABID-seq platform for mapping brain-cell interactions. The approach combines barcoded viral tracing with single-cell RNA sequencing to characterize communication across neuronal and non-neuronal cell types. Seed extensions typically reflect both early scientific validation and the need to fund deeper biology and platform refinement before larger rounds. For the company, the capital supports continued assay development and likely expands preclinical datasets that can inform therapeutic target selection. As multi-omics and cell-interaction mapping become increasingly central to neurodevelopmental and neurodegenerative drug discovery, RABID-seq aims to provide more direct evidence of cellular pathways than standard transcriptomics alone.